

## Analysis of $\Delta^8$ and $\Delta^9$ -THC Metabolites and Other Cannabinoids in Urine


Emily Eng\* and Stephanie Reichardt | UCT, Inc.


## INTRODUCTION


In recent years, there has been a notable increase in the use and commercialization of  $\Delta^8$ -THC. This increase stems from the passing of the Farm Bill of 2018 which legalized hemp. The main cannabinoid of hemp is CBD which can be converted into  $\Delta^8$ -THC. Labs worked to be able to separate parent THC isomers  $\Delta^8$  and  $\Delta^9$ -THC. However, tetrahydrocannabinol (THC) is extensively metabolized by the body into 11-nor-9-carboxy-THC (COOH-THC) and 11-hydroxy-THC (OH-THC). Therefore, quantitation and identification of THC's metabolites is critical for proper identification and interpretation. The newest challenge many laboratories face is the separation of the isomeric metabolites  $\Delta^8$ -COOH-THC,  $\Delta^9$ -COOH-THC and  $\Delta^8$ -OH-THC and  $\Delta^9$ -OH-THC.

Additionally with the expanding cannabis market, new cannabinoids continue to emerge. One example includes,  $\Delta^{10}$  and  $\Delta^{6a,10a}$ -THC which occur naturally in marijuana at low levels, but can be artificially synthesized. THC-O-acetate (THC-O) is a new semi-synthetic cannabinoid that is synthesized by adding acetic anhydride to THC. These three examples are included in the panel with other emerging cannabinoids.

## INSTRUMENT PARAMETERS LC-MS/MS System Shimadzu Nexera LC-30AD with MS-8050 **HPLC Column** SelectraCore® PFPP Column 100 x 2.1 mm, 2.7 µm (PN: SCS27-PFP1021) **Guard Column** SelectraCore® PFPP Guard Column 5 x 2.1 mm, 2.7 µm (PN: SCS27-PFPGDC21) **Column Temperature** 35°C **Flow Rate** 0.3 mL/min **Injection Volume** 10 μL **Mobile Phase A** 5 mM Ammonium Formate + 0.1% Formic Acid in DI H<sub>2</sub>O **Mobile Phase B** Methanol Gradient Conc. B 45% (0 min) - 70% (6 min) - 75% (19-24.5 min) - 45% (24.6-27.6 min)









Disclosure: The speaker, author, moderator, planning member and/or presenter/s do have financial relationships with UCT, Inc., as defined in the AACC policy on potential bias or conflict of interest. The specific product/s: Styre Screen® HLB and the SelectraCore® column will be mentioned and/or discussed.

RESULTS		5 ng/mL			25 ng/mL			50 ng/mL		
URINE n=3	Recovery	Matrix Effect	RSD	Recovery	Matrix Effect	RSD	Recovery	Matrix Effect	RSD	
11-OH-Δ <sup>8</sup> -THC	104%	-20%	3%	83%	-6%	11%	88%	-3%	10%	
11-COOH-Δ <sup>8</sup> -THC	99%	-16%	4%	83%	-4%	8%	84%	-1%	6%	
11-OH-Δ <sup>9</sup> -THC	99%	-11%	2%	83%	0%	14%	86%	6%	8%	
11-COOH-Δ <sup>9</sup> -THC	105%	-21%	13%	82%	-9%	10%	86%	-8%	8%	
CBD	118%	-24%	6%	85%	-12%	8%	85%	-7%	8%	
Δ <sup>8</sup> -THCB	106%	-14%	4%	85%	-8%	11%	83%	4%	8%	
Δ <sup>9</sup> -THCB	106%	-18%	4%	84%	-9%	13%	84%	7%	9%	
exo-THC	104%	-8%	7%	86%	-1%	15%	84%	4%	9%	
Δ <sup>8</sup> -THC	108%	-13%	5%	87%	2%	13%	86%	6%	7%	
Δ <sup>9</sup> -THC	106%	-20%	3%	86%	3%	10%	84%	7%	9%	
Δ <sup>10</sup> -THC/Δ <sup>6a,10a</sup> -THC	110%	14%	2%	83%	25%	9%	90%	11%	6%	
CBN	97%	-2%	3%	80%	5%	13%	78%	3%	7%	
Δ <sup>8</sup> -THCP	111%	-15%	4%	85%	-4%	11%	83%	-2%	9%	
Δ <sup>9</sup> -THCP	109%	-16%	2%	88%	-7%	10%	85%	-6%	9%	
Δ <sup>8</sup> -THC-O-Acetate	117%	-13%	1%	95%	-8%	3%	87%	-11%	3%	
Δ <sup>9</sup> -THC-O-Acetate	117%	-19%	1%	96%	-16%	4%	90%	-3%	4%	

[1] "5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC." U.S. Food and Drug Administration, 4 May 2022, www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc.

[2] Mallen, Briana. "Is Delta 10 Natural or Synthetic?" Secret Nature, 1 Sept. 2021, secretnaturecbd.com/blogs/cbd/is-delta-10-natural-or-synthetic.

[3] Alaina K Holt and others, Δ<sup>8</sup> -THC, THC-O Acetates and CBD-di-O Acetate: Emerging Synthetic Cannabinoids Found in Commercially Sold Plant Material and Gummy Edibles, Journal of Analytical Toxicology, Volume 46, Issue 8, October 2022, Pages 940–948, https://doi.org/10.1093/jat/bkac036

## CONCLUSION

Questions / Comments: methods@unitedchem.com

UCT's SelectraCore® PFPP column and methanol as mobile phase B proved to be the best combination to achieve separation of the four isomeric metabolites. This method separated a total of 16 cannabinoids. Unfortunately, the PFPP column was not able to separate  $\Delta^{10}$ -THC and  $\Delta^{6a,10a}$ -THC. Additionally, baseline separation of the THC-O-Acetate isomers were also not achieved. Analytes were extracted from urine utilizing UCT's Styre Screen® HLB solid phase extraction column. After optimization, the extraction's recovery, matrix effect, and relative standard deviation were evaluated at three concentrations (5, 25, 50 ng/mL). Recoveries for all analytes were acceptable, above 75% (range 78-118%). Matrix effects and relative standard deviations were within ANSI/ASB Standard 063 guidelines. Matrix effects were within  $\pm$  25% and the RSDs were less than 20% (range 1-15%).